| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 342.29 | 278.63 |
| Pretax Income | 80.44 | 44.60 |
| Net Income | 53.52 | 71.78 |
| Diluted EPS | 0.31 | 0.42 |
- Net Income YoY
- -25.4%
Key highlights
- Total revenue climbed to $342.29 million, a 22.8% increase from $278.63 million in Q3 2025
- Pretax income expanded to $80.44 million, up from $44.60 million in the prior year period
- Net income for the quarter was $53.52 million, reflecting a year-over-year decline of 25.4%
- Diluted earnings per share decreased to $0.31 from $0.42 in the same quarter last year
- Management provided full-year 2026 revenue guidance between $1,265 million and $1,295 million
How the Period Went
Acadia Pharmaceuticals reported total revenue of $342.29 million for the third quarter of 2026, representing a 22.8% increase over the $278.63 million recorded in the same period last year. This growth was accompanied by a substantial rise in pretax income, which reached $80.44 million compared to $44.60 million in the prior year. However, net income for the quarter declined by 25.4% to $53.52 million, down from $71.78 million in Q3 2025. This resulted in a diluted earnings per share of $0.31, a decrease from the $0.42 reported twelve months prior, as the company balanced revenue expansion with shifting bottom-line dynamics.
Margins and Profitability
The company demonstrated improved operational leverage as pretax income nearly doubled year-over-year. This performance suggests a significant expansion in pretax margins, driven by higher sales volumes of commercial products and disciplined management of operating expenses. Despite the growth at the pretax level, the final net income figure was $53.52 million, affected by tax or non-operating items that caused it to diverge from the pretax trend. Acadia continues to transition toward sustained profitability, utilizing the cash flow generated by its established Parkinson's disease psychosis and Rett syndrome franchises to fund ongoing late-stage clinical development.
Business Overview
- Specializes in small-molecule drug development for central nervous system disorders
- Commercial portfolio led by NUPLAZID for Parkinson’s disease psychosis
- Commercial portfolio includes DAYBUE, the first treatment approved for Rett syndrome
- Pipeline focuses on unmet needs in neurology and psychiatry segments
- Upcoming milestones include Phase 2 RADIANT study data for remlifanserin in late 2026
Financial Context
With a market capitalization of approximately $3.71 billion, Acadia is currently trading at a price-to-earnings ratio of 9.63x. This valuation follows a period of sequential revenue growth throughout 2026, with the Q3 result of $342.29 million exceeding the $308.0 million and $268.0 million reported in the second and first quarters, respectively. While the stock has experienced a 16.17% decline over the past quarter, it has shown recent upward momentum with a 6.76% gain over the last month. The company's updated full-year revenue guidance suggests a stable outlook for its primary commercial products through the end of the fiscal year.
Down 13.0% since our story on 5 Nov: $21.47 when we broke it → $18.67 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $19.80 |
|---|---|
| 20 Oct | $20.44 |
| 21 Oct | $20.19 |
| 22 Oct | $20.31 |
| 23 Oct | $19.73 |
| 26 Oct | $19.74 |
| 27 Oct | $20.17 |
| 28 Oct | $20.32 |
| 29 Oct | $20.76 |
| 30 Oct | $20.59 |
| 2 Nov | $20.47 |
| 3 Nov | $20.57 |
| 4 Nov | $21.47 |
| 5 Nov | $21.24 |
| 6 Nov | $21.23 |
| 9 Nov | $16.50 |
| 10 Nov | $18.28 |
| 11 Nov | $18.37 |
| 12 Nov | $18.14 |
| 13 Nov | $18.75 |
| 16 Nov | $18.67 |
Industry Landscape
The biotechnology sector remains focused on specialized orphan drugs, where Acadia maintains a strong footprint. Industry conditions are characterized by steady demand for CNS therapies, though competition for market share in specialized neurology remains high. Acadia's P/E ratio of 9.63x is relatively low compared to many biotech peers, reflecting a market positioning that balances commercial execution with clinical development risk. As the sector faces rigorous regulatory standards, Acadia’s ability to generate significant commercial revenue from two distinct products provides a diversified base relative to single-product development-stage companies.
| Date | Announcement | Amount |
|---|---|---|
| 04 Nov 2026 | Q3 2026 total revenuesSource: businesswire.com | $342.0 Million |
| 04 Aug 2026 | Q2 2026 total revenuesSource: morningstar.com | $308.0 Million |
| 06 May 2026 | Q1 2026 total revenuesSource: acadia.com | $268.0 Million |
| 25 Feb 2026 | Q4 2025 total revenuesSource: ir.acadia.com | $284.0 Million |
| 05 Nov 2025 | Q3 2025 total revenuesSource: businesswire.com | $278.6 Million |
| 06 Aug 2025 | Q2 2025 total revenuesSource: businesswire.com | $264.6 Million |
| Share price | $21.47 |
|---|---|
| Market cap | $3.7B |
| Revenue (annual) | $1.1B |
| P/E (TTM) | 9.6× |
| 1-month price change | +6.76% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Acadia Pharmaceuticals Inc. announcing third quarter 2026 financial results.
Track ACADIA PHARMACEUTICALS INC live
Get the next ACADIA PHARMACEUTICALS INC SEC filing seconds after it lands.



